Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Breast 1

Conditions

Endometrial Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Breast Diseases 1

Interventions

pembrolizumab 35Paclitaxel 10Nivolumab 10Carboplatin 9atezolizumab 7Docetaxel 7Cisplatin 7Ipilimumab 5Gemcitabine 5Cyclophosphamide 5spartalizumab 4fludarabine 4Fluorouracil 4lenvatinib 3durvalumab 3cemiplimab 3avelumab 3Vorinostat 3Trastuzumab 3Oxaliplatin 3Leucovorin 3Immunoglobulin G 3Fulvestrant 3Cetuximab 3Bevacizumab 3zimberelimab 2tisotumab vedotin 2tislelizumab 2sargramostim 2aldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Imlunestrant × Gynecologic × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡